Endotech vs Daisy Global:
Are They the Same Company?
Short answer: No. Endotech is the technology. Daisy Global was a separate company that used that technology. If you read negative Daisy Global reviews and assumed they were about Endotech, this page explains exactly what happened and why the two should not be confused.
Endotech and Daisy Global are separate companies
Endotech is an AI trading technology company founded in 2012 by Dr. Anna Becker. Daisy Global was a crowdfunding platform created in 2021 that licensed Endotech's technology. Different founders, different legal entities, different business models, different custody structures. The Daisy Global withdrawal problems were caused by Daisy Global's own operational failures — not Endotech's trading performance.
The Relationship Between Endotech and Daisy Global — Explained Clearly
Think of it this way. AWS (Amazon Web Services) provides cloud infrastructure. Thousands of companies build their products on top of AWS. If one of those companies goes bankrupt or fails its customers, that is not Amazon's fault. AWS's technology kept working perfectly. The problem was the company that built on top of it.
This is the Endotech and Daisy Global relationship exactly. Endotech built the AI trading technology. Daisy Global was a crowdfunding platform that incorporated Endotech's technology into its product offering. The people who had problems with Daisy Global — withdrawal delays, account access issues, KYC problems — were having problems with Daisy Global's platform and operations. Not with Endotech's AI.
Endotech's trading algorithms continued operating throughout the Daisy Global issues. The AI's performance record — 8 years, zero losing years, 163% average annual on BTC Alpha — was not affected by Daisy Global's operational collapse. The technology worked. The platform built on top of it failed.
Timeline — What Actually Happened
Dr. Anna Becker founds Endotech in Israel. Begins developing institutional AI trading algorithms serving hedge funds and accredited investors. Technology operates on a fixed capital basis, consistently generating returns.
After building the infrastructure from 2012, Endotech moves into cryptocurrency markets in 2017. BTC Alpha strategy begins live operation. 83% trade accuracy established through this period. $40M in development capital deployed.
Daisy Global — a separate company with separate founders — launches a crowdfunding platform that licenses Endotech's AI technology. Daisy Global holds customer funds in its own structure and allocates them to Endotech's strategies. The custody model is Daisy Global's — not Endotech's. This distinction becomes critical later.
Daisy Global encounters KYC compliance requirements and operational difficulties that result in withdrawal delays for its customers. These problems are entirely within Daisy Global's platform — Endotech's AI technology was not the cause. Negative reviews begin accumulating on Trustpilot, many incorrectly attributing Daisy Global's problems to Endotech.
Endotech enters an exclusive retail partnership with Bit1 Exchange. The fundamental structural difference: your funds stay in your own Bit1 Futures wallet. Endotech connects via trade-only API. No pooled funds. No third party holding your capital. The Daisy Global custody problem structurally cannot exist in this model.
Side-by-Side Comparison — Daisy Global vs Bit1 Exchange Model
| Factor | Daisy Global (old model) | Bit1 Exchange (current model) |
|---|---|---|
| Who holds your funds | Daisy Global (third party) | You — in your own wallet |
| Withdrawal control | Controlled by Daisy Global | Withdraw anytime, no restrictions |
| API model | Pooled fund allocation | Trade-only API — no withdrawal access |
| KYC/compliance dependency | Daisy Global compliance required | Your own Bit1 account — your control |
| Can funds be frozen? | Yes — Daisy Global controlled this | No — Endotech cannot access funds |
| Exchange infrastructure | Daisy Global platform | ChainUp (same as OKX, Bybit) |
| Minimum to start | $50,000+ (institutional) | No minimum |
| Post-FTX custody model | No — similar risk profile | Yes — structural opposite of FTX |
The reason Daisy Global reviews don't apply to the Bit1 Exchange model is structural — the custody architecture is completely different.
Why the Negative Reviews Don't Apply to the Current Model
These withdrawals were controlled by Daisy Global, not Endotech. On Bit1 Exchange, withdrawals are controlled entirely by you. Endotech's API cannot touch your funds. This problem cannot exist in the current model.
ScamAdviser uses automated metadata scoring. Endotech scores low because it is registered in Israel, uses privacy protection, and operates in crypto. Their algorithm automatically penalises all three. Scam-Detector.com gives the same company 90.9/100. Neither has reviewed the actual trading operations.
This review's actual basis: no MT4 platform, no demo account, previously high minimums. These are criticisms of their old retail model — not fraud. Endotech is an institutional AI system, not a forex broker. The Bit1 partnership has eliminated the high minimum problem entirely — there is no minimum to connect.
What You Should Actually Evaluate
The relevant question is not whether Daisy Global had problems. It did. The relevant question is whether the current Endotech model through Bit1 Exchange has the same structural vulnerabilities that caused those problems. It does not.
The three things that caused Daisy Global's failure — pooled custody, third-party fund control, and single-company withdrawal authority — are all structurally absent from the Bit1 Exchange model. Your funds stay in your own Bit1 Futures wallet. Endotech connects via trade-only API. You can withdraw at any moment.
The legitimate things to evaluate about the current Bit1/Endotech model are: the 8-year track record (real and verifiable), the performance fee structure (50% of profits, no subscription), the Bit1 Exchange's newer status compared to Binance, and the inherent volatility of cryptocurrency markets. Those are real considerations. The Daisy Global custody failures are not.
For the full research and performance analysis, see our complete Endotech AI review and the institutional AI deep review.
About Dr. Anna Becker — The Endotech Founder
Understanding who built this system is central to evaluating it. Dr. Anna Becker holds a PhD in computer science and AI from the Technion Institute of Technology — Israel's equivalent of MIT. She conducted research with AXA and BNP Paribas. She co-authored a published book on Bayesian networks that has legitimate academic citations. She founded Strategy Runner, a fintech company for algorithmic investing that was acquired by MF Global in 2011 for $3.75 million — a real transaction documented on Finance Magnates, from before crypto existed as an investment category.
This is a 20-year paper trail. It predates the cryptocurrency industry entirely. It cannot have been fabricated to promote a crypto project. The founder is real, credentialed, and verifiable. For the complete profile, see our Dr. Anna Becker page.
Frequently Asked Questions
Your Funds Stay in Your Wallet. Always.
8 years live · Zero losing years · Full self-custody · Free to join
VIEW SETUP GUIDE — FREEPast performance does not guarantee future results. Crypto trading carries risk.